Abstract:HBV capsid assembly has been viewed as an attractive target for new antiviral therapies against HBV. On the basis of a lead compound 4r, we further investigated this target to identify novel active compounds with appropriate anti-HBV potencies and improved pharmacokinetic (PK) properties. Structure–activity relationship studies based on metabolic pathways of 4r led to the identification of a phthalazinone derivative 19f with appropriate anti-HBV potencies (IC50 = 0.014 ± 0.004 μM in vitro), which demonstrated high oral bioavailability and liver exposure. In the AAV-HBV/mouse model, administration of 19f resulted in a 2.67 log reduction of the HBV DNA viral load during a 4-week treatment with 150 mg/kg dosing twice daily.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00346?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00346</a>.Tissue distributions profiles and plasma concentration–time curves in mice of 4r, 10m, and 19f; detailed experimental procedures for the synthesis of analogues 10a, 10b, 10i, 10j, 10k and intermediates 18h–18n; characterization (1H NMR spectra and 13C NMR spectra are attached) and HPLC purity control of the selected final compounds 10l, 10m, 18a, 18b, 18d, 18e, 18g, 19a–19h (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf">PDF</a>)Molecular-formula strings of the reported compounds and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

The SAR-based Development of Small Molecular HBV Capsid Assembly Modulators

Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays

Discovery Of (1h-Pyrazolo[3,4-C]Pyridin-5-Yl)Sulfonamide Analogues As Hepatitis B Virus Capsid Assembly Modulators By Conformation Constraint

Development of Benzimidazole-Based Compounds As Novel Capsid Assembly Modulators for the Treatment of HBV Infection

Design, synthesis and anti-HBV activity study of novel HBV capsid assembly modulators

Pharmacophore-Based Virtual Screening and Structural Modification of Novel Benzamide Derivatives as HBV Capsid Assembly Modulators

Structure-Based Discovery of <i>N</i>-Sulfonylpiperidine-3-Carboxamides as Novel Capsid Assembly Modulators for Potent Inhibition of HBV Replication

Design, synthesis and biological evaluation of novel dihydrobenzodioxine derivatives as HBV capsid protein inhibitors

Discovery of novel small molecules targeting hepatitis B virus core protein from marine natural products with HiBiT-based high-throughput screening

Synthesis and evaluation of N-sulfonylpiperidine-3-carboxamide derivatives as capsid assembly modulators inhibiting HBV in vitro and in HBV-transgenic mice

Small Molecule Assembly Agonist Alters the Dynamics of Hepatitis B Virus Core Protein Dimer and Capsid

An automated microfluidic platform for the screening and characterization of novel hepatitis B virus capsid assembly modulators

Optimization and Synthesis of Pyridazinone Derivatives As Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation

Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors

An Aptamer Targets Hbv Core Protein And Suppresses Hbv Replication In Hepg2.2.15 Cells

Metabolically Improved Stem Cell Derived Hepatocyte-Like Cells Support HBV Life Cycle and Are a Promising Tool for HBV Studies and Antiviral Drug Screenings

cccDNA-Targeted Drug Screen Reveals a Class of Antihistamines as Suppressors of HBV Genome Levels

Development of anti-HBV agents targeting HBV capsid proteins

A novel phthalazinone derivative as a capsid assembly modulator inhibits hepatitis B virus expression